Clinical Trial Update: Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating once-daily versus twice-daily budesonide orodispersible tablets for induction of remission in eosinophilic esophagitis an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Esophagitis

Drugs mentioned

• Budesonide orodispersible tablet (once-daily vs twice-daily dosing) (budesonide)

Snippet

Sponsor: Dr. Falk Pharma GmbH | Conditions: Eosinophilic Esophagitis | Phase 3 | Status: RECRUITING